The Entrada Group

Entrada Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of devastating diseases by establishing a new class of medicines that engage intracellular targets. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the efficient delivery of a wide range of therapeutic modalities—including oligonucleotides, antibodies, and enzymes—into cells, overcoming the historical challenge of reaching "undruggable" intracellular targets. Its lead programs target neuromuscular diseases, specifically Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Entrada is advancing a robust pipeline, including ENTR-601-44 and ENTR-601-45 for DMD, and maintains a significant strategic partnership with Vertex Pharmaceuticals for its DM1 program.